Inflammatory Pathways in Spinal Cord Injury

International Review of Neurobiology

Volumn 106, Issue , 2012, Pages 127-152

  David, Samuel ^a   Zarruk, Juan Guillermo ^a   Ghasemlou, Nader ^b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Inflammation; KCa3.1; Macrophage; MAPK activated protein kinase 2; Microglia; Secondary damage; Secretory leukocyte protease inhibitor; Spinal cord injury

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; AX 059; AX 115; CALCIUM ACTIVATED POTASSIUM CHANNEL; CYTOKINE; FKGK 11; GK 115; KCA3.1 CHANNEL BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE ACTIVATED PROTEIN KINASE 2; OMEGA CONOTOXIN GVIA; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; PROTEIN KCA3.1; PROTEIN KCNN4; RECOMBINANT PROTEIN; RECOMBINANT SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; BRAIN EDEMA; BRAIN INFARCTION; CENTRAL NERVOUS SYSTEM; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; INTRACRANIAL HYPERTENSION; LOCOMOTION; MACROPHAGE ACTIVATION; MICROARRAY ANALYSIS; NERVE DEGENERATION; NERVE FIBER REGENERATION; NERVE INJURY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; SUBDURAL HEMATOMA; TISSUE INJURY;

EID: 84870502415     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407178-0.00006-5     Document Type: Chapter

References (105)

1. Ankeny D.P., Lucin K.M., Sanders V.M., McGaughy V.M., Popovich P.G. Spinal cord injury triggers systemic autoimmunity: Evidence for chronic B lymphocyte activation and lupus-like autoantibody synthesis. Journal of Neurochemistry 2006, 99:1073-1087.
2. Ankeny D.P., Popovich P.G. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience 2009, 158:1112-1121.
3. Ashcroft G.S., Lei K., Jin W., Longenecker G., Kulkarni A.B., Greenwell-Wild T., et al. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nature Medicine 2000, 6:1147-1153.
4. Bao F., Chen Y., Dekaban G.A., Weaver L.C. Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats. Journal of Neurochemistry 2004, 88:1335-1344.
5. Bao F., Chen Y., Schneider K.A., Weaver L.C. An integrin inhibiting molecule decreases oxidative damage and improves neurological function after spinal cord injury. Experimental Neurology 2008, 214:160-167.
6. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. Journal of Neurotrauma 2006, 23:635-659.
7. Bonventre J.V., Huang Z., Taheri M.R., O'Leary E., Li E., Moskowitz M.A., et al. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997, 390:622-625.
8. Bouhy D., Ghasemlou N., Lively S., Redensek A., Rathore K.I., Schlichter L.C., et al. Inhibition of the Ca(2)(+)-dependent K(+) channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury. The Journal of Neuroscience 2011, 31:16298-16308.
9. Brown W.J., Chambers K., Doody A. Phospholipase A2 (PLA2) enzymes in membrane trafficking: Mediators of membrane shape and function. Traffic 2003, 4:214-221.
10. Casas J., Gijon M.A., Vigo A.G., Crespo M.S., Balsinde J., Balboa M.A. Overexpression of cytosolic group IVA phospholipase A2 protects cells from Ca2+-dependent death. The Journal of Biological Chemistry 2006, 281:6106-6116.
11. Chen Y.J., Raman G., Bodendiek S., O'Donnell M.E., Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. Journal of Cerebral Blood Flow and Metabolism 2011, 31:2363-2374.
12. Chrestensen C.A., Schroeder M.J., Shabanowitz J., Hunt D.F., Pelo J.W., Worthington M.T., et al. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. The Journal of Biological Chemistry 2004, 279:10176-10184.
13. Courtine G., Song B., Roy R.R., Zhong H., Herrmann J.E., Ao Y., et al. Recovery of supraspinal control of stepping via indirect propriospinal relay connections after spinal cord injury. Nature Medicine 2008, 14:69-74.
14. David S., Greenhalgh A.D., Lopez-Vales R. Role of phospholipase A(2)s and lipid mediators in secondary damage after spinal cord injury. Cell and Tissue Research 2012, 349:249-267.
15. David S., Kroner A. Repertoire of macrophage-microglial responses after spinal cord injury - impact on repair. Nature Reviews Neuroscience 2011, 12:388-399.
16. David S., Lacroix S. Molecular approaches to spinal cord repair. Annual Review of Neuroscience 2003, 26:411-440.
17. David S., Ousman S.S. Recruiting the immune response to promote axon regeneration in the injured spinal cord. The neuroscientist: A review journal bringing neurobiology, neurology and psychiatry 2002, 8:33-41.
18. Denes A., Thornton P., Rothwell N.J., Allan S.M. Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. Brain, Behavior, and Immunity 2010, 24:708-723.
19. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Experimental Neurology 2008, 209:378-388.
20. Fischer D., Hauk T.G., Muller A., Thanos S. Crystallins of the beta/gamma-superfamily mimic the effects of lens injury and promote axon regeneration. Molecular and Cellular Neurosciences 2008, 37:471-479.
21. Fleming J.C., Bao F., Cepinskas G., Weaver L.C. Anti-alpha4beta1 integrin antibody induces receptor internalization and does not impair the function of circulating neutrophilic leukocytes. Inflammation Research 2010, 59:647-665.
22. Fleming J.C., Norenberg M.D., Ramsay D.A., Dekaban G.A., Marcillo A.E., Saenz A.D., et al. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269.
23. Fordyce C.B., Jagasia R., Zhu X., Schlichter L.C. Microglia Kv1.3 channels contribute to their ability to kill neurons. The Journal of Neuroscience 2005, 25:7139-7149.
24. Forlenza O.V., Mendes C.T., Marie S.K., Gattaz W.F. Inhibition of phospholipase A2 reduces neurite outgrowth and neuronal viability. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2007, 76:47-55.
25. Gaestel M. MAPKAP kinases - MKs - two's company, three's a crowd. Nature Reviews. Molecular Cell Biology 2006, 7:120-130.
26. Gardos G. The function of calcium in the potassium permeability of human erythrocytes. Biochimica et Biophysica Acta 1958, 30:653-654.
27. Gelderblom M., Leypoldt F., Steinbach K., Behrens D., Choe C.-U., Siler D., et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40:1849-1906.
28. Genovese T., Mazzon E., Crisafulli C., Di Paola R., Muia C., Esposito E., et al. TNF-alpha blockage in a mouse model of SCI: Evidence for improved outcome. Shock 2008, 29:32-41.
29. George R., Griffin J.W. Delayed macrophage responses and myelin clearance during Wallerian degeneration in the central nervous system: The dorsal radiculotomy model. Experimental Neurology 1994, 129:225-236.
30. Ghasemlou N., Bouhy D., Yang J., Lopez-Vales R., Haber M., Thuraisingam T., et al. Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain 2010, 133:126-138.
31. Ghasemlou N., Lopez-Vales R., Lachance C., Thuraisingam T., Gaestel M., Radzioch D., et al. Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury. The Journal of Neuroscience 2010, 30:13750-13759.
32. Gomez-Nicola D., Valle-Argos B., Pita-Thomas D.W., Nieto-Sampedro M. Interleukin 15 expression in the CNS: Blockade of its activity prevents glial activation after an inflammatory injury. Glia 2008, 56:494-505.
33. Gris D., Marsh D.R., Oatway M.A., Chen Y., Hamilton E.F., Dekaban G.A., et al. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. The Journal of Neuroscience 2004, 24:4043-4051.
34. Hitti E., Iakovleva T., Brook M., Deppenmeier S., Gruber A.D., Radzioch D., et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Molecular and Cellular Biology 2006, 26:2399-2407.
35. Horiuchi H., Ogata T., Morino T., Chuai M., Yamamoto H. Continuous intrathecal infusion of SB203580, a selective inhibitor of p38 mitogen-activated protein kinase, reduces the damage of hind-limb function after thoracic spinal cord injury in rat. Neuroscience Research 2003, 47:209-217.
36. Hsu J.Y., McKeon R., Goussev S., Werb Z., Lee J.U., Trivedi A., et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. The Journal of Neuroscience 2006, 26:9841-9850.
37. Jin F.Y., Nathan C., Radzioch D., Ding A. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997, 88:417-426.
38. Kalyvas A., Baskakis C., Magrioti V., Constantinou-Kokotou V., Stephens D., Lopez-Vales R., et al. Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain 2009, 132:1221-1235.
39. Karimi-Abdolrezaee S., Billakanti R. Reactive astrogliosis after spinal cord injury-band detrimental effects. Molecular Neurobiology 2012, 46:251-264.
40. Kaushal V., Koeberle P.D., Wang Y., Schlichter L.C. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. The Journal of Neuroscience 2007, 27:234-244.
41. Kaushal V., Schlichter L.C. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. The Journal of Neuroscience 2008, 28:2221-2230.
42. Khanna R., Chang M.C., Joiner W.J., Kaczmarek L.K., Schlichter L.C. hSK4/hIK1, a calmodulin-binding KCa channel in human T lymphocytes. Roles in proliferation and volume regulation. The Journal of Biological Chemistry 1999, 274:14838-14849.
43. Kigerl K.A., Gensel J.C., Ankeny D.P., Alexander J.K., Donnelly D.J., Popovich P.G. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. The Journal of Neuroscience 2009, 29:13435-13444.
44. Kigerl K.A., McGaughy V.M., Popovich P.G. Comparative analysis of lesion development and intraspinal inflammation in four strains of mice following spinal contusion injury. The Journal of Comparative Neurology 2006, 494:578-594.
45. Kotlyarov A., Neininger A., Schubert C., Eckert R., Birchmeier C., Volk H.D., et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nature Cell Biology 1999, 1:94-97.
46. Lazarov-Spiegler O., Solomon A.S., Schwartz M. Peripheral nerve-stimulated macrophages simulate a peripheral nerve-like regenerative response in rat transected optic nerve. Glia 1998, 24:329-337.
47. Lazarov-Spiegler O., Solomon A.S., Zeev-Brann A.B., Hirschberg D.L., Lavie V., Schwartz M. Transplantation of activated macrophages overcomes central nervous system regrowth failure. FASEB Journal 1996, 10:1296-1302.
48. Lentsch A.B., Jordan J.A., Czermak B.J., Diehl K.M., Younkin E.M., Sarma V., et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. The American Journal of Pathology 1999, 154:239-247.
49. Leon S., Yin Y., Nguyen J., Irwin N., Benowitz L.I. Lens injury stimulates axon regeneration in the mature rat optic nerve. The Journal of Neuroscience 2000, 20:4615-4626.
50. Liu N.K., Zhang Y.P., Titsworth W.L., Jiang X., Han S., Lu P.H., et al. A novel role of phospholipase A2 in mediating spinal cord secondary injury. Annals of Neurology 2006, 59:606-619.
51. Lopez-Vales R., Ghasemlou N., Redensek A., Kerr B.J., Barbayianni E., Antonopoulou G., et al. Phospholipase A2 superfamily members play divergent roles after spinal cord injury. FASEB Journal 2011, 25:4240-4252.
52. Mahtani K.R., Brook M., Dean J.L., Sully G., Saklatvala J., Clark A.R. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Molecular and Cellular Biology 2001, 21:6461-6469.
53. Mauler F., Hinz V., Horvath E., Schuhmacher J., Hofmann H.A., Wirtz S., et al. Selective intermediate-/small-conductance calcium-activated potassium channel (KCNN4) blockers are potent and effective therapeutics in experimental brain oedema and traumatic brain injury caused by acute subdural haematoma. The European Journal of Neuroscience 2004, 20:1761-1768.
54. Muller A., Hauk T.G., Fischer D. Astrocyte-derived CNTF switches mature RGCs to a regenerative state following inflammatory stimulation. Brain 2007, 130:3308-3320.
55. Murakami M., Kudo I. Diversity and regulatory functions of mammalian secretory phospholipase A2s. Advances in Immunology 2001, 77:163-194.
56. Murakami M., Nakatani Y., Atsumi G., Inoue K., Kudo I. Regulatory functions of phospholipase A2. Critical Reviews in Immunology 1997, 17:225-283.
57. Naruo S., Okajima K., Taoka Y., Uchiba M., Nakamura T., Okabe H., et al. Prostaglandin E1 reduces compression trauma-induced spinal cord injury in rats mainly by inhibiting neutrophil activation. Journal of Neurotrauma 2003, 20:221-228.
58. Neininger A., Kontoyiannis D., Kotlyarov A., Winzen R., Eckert R., Volk H.D., et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. The Journal of Biological Chemistry 2002, 277:3065-3068.
59. Nito C., Kamada H., Endo H., Niizuma K., Myer D., Chan P. Role of the p38 mitogen-activated protein kinase/cytosolic phospholipase A2 signaling pathway in blood-brain barrier disruption after focal cerebral ischemia and reperfusion. Journal of Cerebral Blood Flow and Metabolism 2008, 28:1686-1782.
60. Noble L.J., Donovan F., Igarashi T., Goussev S., Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. The Journal of Neuroscience 2002, 22:7526-7535.
61. Norenberg M.D., Smith J., Marcillo A. The pathology of human spinal cord injury: Defining the problems. Journal of Neurotrauma 2004, 21:429-440.
62. Nwomeh B.C., Yager D.R., Cohen I.K. Physiology of the chronic wound. Clinics in Plastic Surgery 1998, 25:341-356.
63. Offer S., Yedgar S., Schwob O., Krimsky M., Bibi H., Eliraz A., et al. Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats. The American Journal of Physiology 2005, 288:L523-L529.
64. Oikawa Y., Yamato E., Tashiro F., Yamamoto M., Uozumi N., Shimada A., et al. Protective role for cytosolic phospholipase A2alpha in autoimmune diabetes of mice. FEBS Letters 2005, 579:3975-3978.
65. Ousman S.S., David S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 2000, 30:92-104.
66. Ousman S.S., David S. MIP-1alpha, MCP-1, GM-CSF, and TNF-alpha control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. The Journal of Neuroscience 2001, 21:4649-4656.
67. Perrin F.E., Lacroix S., Aviles-Trigueros M., David S. Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1alpha and interleukin-1beta in Wallerian degeneration. Brain 2005, 128:854-866.
68. Pineau I., Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: Multiphasic expression pattern and identification of the cell types involved. The Journal of Comparative Neurology 2007, 500:267-285.
69. Pineau I., Sun L., Bastien D., Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain, Behavior, and Immunity 2010, 24:540-553.
70. Popovich P.G., Guan Z., Wei P., Huitinga I., van Rooijen N., Stokes B.T. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Experimental Neurology 1999, 158:351-365.
71. Rapalino O., Lazarov-Spiegler O., Agranov E., Velan G.J., Yoles E., Fraidakis M., et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nature Medicine 1998, 4:814-821.
72. Reich E.P., Cui L., Yang L., Pugliese-Sivo C., Golovko A., Petro M., et al. Blocking ion channel KCNN4 alleviates the symptoms of experimental autoimmune encephalomyelitis in mice. European Journal of Immunology 2005, 35:1027-1036.
73. Rice T., Larsen J., Rivest S., Yong V.W. Characterization of the early neuroinflammation after spinal cord injury in mice. Journal of Neuropathology and Experimental Neurology 2007, 66:184-195.
74. Rotshenker S. Wallerian degeneration: The innate-immune response to traumatic nerve injury. Journal of Neuroinflammation 2011, 8:109.
75. Sallenave J.M. Secretory leukocyte protease inhibitor and elafin/trappin-2: Versatile mucosal antimicrobials and regulators of immunity. American Journal of Respiratory Cell and Molecular Biology 2010, 42:635-643.
76. Schwartz M., Moalem G., Leibowitz-Amit R., Cohen I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends in Neurosciences 1999, 22:295-299.
77. Schwartz M., Yoles E. Immune-based therapy for spinal cord repair: Autologous macrophages and beyond. Journal of Neurotrauma 2006, 23:360-370.
78. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology 2008, 8:349-361.
79. Silver J., Miller J.H. Regeneration beyond the glial scar. Nature Reviews. Neuroscience 2004, 5:146-156.
80. Song X., Zeng L., Jin W., Thompson J., Mizel D.E., Lei K., et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. The Journal of Experimental Medicine 1999, 190:535-542.
81. Sroga J.M., Jones T.B., Kigerl K.A., McGaughy V.M., Popovich P.G. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. The Journal of Comparative Neurology 2003, 462:223-240.
82. Stadelmann W.K., Digenis A.G., Tobin G.R. Physiology and healing dynamics of chronic cutaneous wounds. The American Journal of Surgery 1998, 176:26S-38S.
83. Stirling D.P., Liu S., Kubes P., Yong V.W. Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. The Journal of Neuroscience 2009, 29:753-764.
84. Stirling D.P., Liu J., Plunet W., Steeves J.D., Tetzlaff W. SB203580, a p38 mitogen-activated protein kinase inhibitor, fails to improve functional outcome following a moderate spinal cord injury in rat. Neuroscience 2008, 155:128-137.
85. Stirling D.P., Yong V.W. Dynamics of the inflammatory response after murine spinal cord injury revealed by flow cytometry. Journal of Neuroscience Research 2008, 86:1944-1958.
86. Stolk J., Rudolphus A., Kramps J.A. Lipopolysaccharide-induced alveolar wall destruction in the hamster is inhibited by intratracheal treatment with r-secretory leukocyte protease inhibitor. Annals of the New York Academy of Sciences 1991, 624:350-352.
87. Stoll G., Griffin J.W., Li C.Y., Trapp B.D. Wallerian degeneration in the peripheral nervous system: Participation of both Schwann cells and macrophages in myelin degradation. Journal of Neurocytology 1989, 18:671-683.
88. Stoll G., Trapp B.D., Griffin J.W. Macrophage function during Wallerian degeneration of rat optic nerve: Clearance of degenerating myelin and Ia expression. The Journal of Neuroscience 1989, 9:2327-2335.
89. Taggart C.C., Cryan S.A., Weldon S., Gibbons A., Greene C.M., Kelly E., et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. The Journal of Experimental Medicine 2005, 202:1659-1668.
90. Taoka Y., Okajima K., Uchiba M., Murakami K., Kushimoto S., Johno M., et al. Role of neutrophils in spinal cord injury in the rat. Neuroscience 1997, 79:1177-1182.
91. Thuraisingam T., Xu Y.Z., Moisan J., Lachance C., Garnon J., Di Marco S., et al. Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands. Molecular Immunology 2007, 44:3482-3491.
92. van den Brand R., Heutschi J., Barraud Q., DiGiovanna J., Bartholdi K., Huerlimann M., et al. Restoring voluntary control of locomotion after paralyzing spinal cord injury. Science 2012, 336:1182-1185.
93. Wang X., Li X., Xu L., Zhan Y., Yaish-Ohad S., Erhardt J.A., et al. Up-regulation of secretory leukocyte protease inhibitor (SLPI) in the brain after ischemic stroke: Adenoviral expression of SLPI protects brain from ischemic injury. Molecular Pharmacology 2003, 64:833-840.
94. Wang Q., Sun A., Pardeike J., Müller R., Simonyi A., Sun G. Neuroprotective effects of a nanocrystal formulation of sPLA(2) inhibitor PX-18 in cerebral ischemia/reperfusion in gerbils. Brain Research 2009, 1285:188-283.
95. Wang Q., Tang X.N., Yenari M.A. The inflammatory response in stroke. Journal of Neuroimmunology 2007, 184:53-68.
96. Wang X., Xu L., Wang H., Young P.R., Gaestel M., Feuerstein G.Z. Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice. The Journal of Biological Chemistry 2002, 277:43968-43972.
97. Winzen R., Kracht M., Ritter B., Wilhelm A., Chen C.Y., Shyu A.B., et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. The EMBO Journal 1999, 18:4969-4980.
98. Xu L., Chen S., Bergan R.C. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006, 25:2987-2998.
99. Xu Z., Wang B.R., Wang X., Kuang F., Duan X.L., Jiao X.Y., et al. ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury. Life Sciences 2006, 79:1895-1905.
100. Yang L., Blumbergs P.C., Jones N.R., Manavis J., Sarvestani G.T., Ghabriel M.N. Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 2004, 29:966-971.
101. Yang L., Jones N.R., Blumbergs P.C., Van Den Heuvel C., Moore E.J., Manavis J., et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. Journal of Clinical Neuroscience 2005, 12:276-284.
102. Yin Y., Cui Q., Li Y., Irwin N., Fischer D., Harvey A.R., et al. Macrophage-derived factors stimulate optic nerve regeneration. The Journal of Neuroscience 2003, 23:2284-2293.
103. Yin Y., Henzl M.T., Lorber B., Nakazawa T., Thomas T.T., Jiang F., et al. Oncomodulin is a macrophage-derived signal for axon regeneration in retinal ganglion cells. Nature Neuroscience 2006, 9:843-852.
104. Zhang Y., DeWitt D.L., McNeely T.B., Wahl S.M., Wahl L.M. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. The Journal of Clinical Investigation 1997, 99:894-900.
105. Zong S., Zeng G., Wei B., Xiong C., Zhao Y. Beneficial effect of interleukin-1 receptor antagonist protein on spinal cord injury recovery in the rat. Inflammation 2012, 35:520-526.